US 2017/0290914 A1Published application

Anti-lag3 antibodies and antigen-binding fragments

AssigneeMerck Sharp & Dohme Corp.

InventorsLinda Liang, Laurence Fayadat-Dilman, Rene De Waal Malefyt, Gopalan Raghunathan

Life of this patent

Estimating the term…

Loading patent…

Abstract

The present invention includes antibodies and antigen-binding fragments thereof that specifically bind to human or cynomolgous monkey LAG3 as well as immunoglobulin chains thereof and polynucleotides encoding the same along with injection devices comprising such antibodies or fragments. Vaccines including such antibodies and fragments as well as compositions comprising the antibodies and fragments (e.g., including anti-PD1 antibodies) are included in the invention. Methods for treating or preventing cancer or infection using such compositions are also provided. In addition, methods for recombinant expression of the antibodies and fragments are part of the present invention.

Claims27

Dependent claims

An antibody or antigen-binding fragment thereof that specifically binds human LAGS comprising:

(a) the CDR1, CDR2, and CDR3 of a VL domain of an immunoglobulin chain that comprises the amino acid sequence set forth in SEQ ID NO:
7, 17, 27, 37, 57, 59, 61, 63, 65, 101, 126, 130, 132, 136, 138, 208, 210, 224, 226, 228, 230, 232, 241, 257, 259, 261, 263, 351, 369, 371, 373, 375, 401, 403, 405, 426, 427, 450-453 or 459-461;
and/or
(b) the CDR1, CDR2, and CDR3 of a VH domain of an immunoglobulin chain that comprises the amino acid sequence set forth in SEQ ID NO:
2, 12, 22, 32, 45, 47, 49, 51, 53, 55, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 103, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 128, 134, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178, 180, 182, 184, 186, 188, 190, 192, 194, 196, 198, 200, 202, 204, 206, 212, 214, 216, 218, 220, 222, 234, 235, 237, 239, 243, 245, 247, 249, 251, 253, 255, 265, 267, 269, 271, 273, 275, 277, 279, 281, 283, 285, 287, 289, 291, 293, 295, 297, 299, 301, 303, 305, 307, 309, 311, 313, 315, 317, 319, 321, 323, 325, 327, 329, 331, 333, 335, 337, 339, 341, 343, 345, 347, 349, 353, 355, 357, 359, 361, 363, 365, 367, 377, 379, 381, 383, 385, 387, 389, 391, 393, 395, 397, 399, 406-419, 434-442, 448, 449, 462, 463 or 464.

2 more elements

An antibody or antigen-binding fragment thereof that specifically binds human LAG3 comprising a light chain immunogoblin, a heavy chain immunogoblin, or both a light and heavy chain immunoglobulin, selected from the group consisting of:

(1)
a light chain immunoglobulin comprising an amino acid sequence having at least 90% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO:
126 or amino acids 21-131 thereof, and/or
a heavy chain immunoglobulin comprising an amino acid sequence having at least 90% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO:
106 or amino acids 1-119 thereof;
(2)
a light chain immunoglobulin comprising an amino acid sequence having at least 90% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO:
126 or amino acids 21-131 thereof, and/or
a heavy chain immunoglobulin comprising an amino acid sequence having at least 90% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO:
108 or amino acids 1-119 thereof;
(3)
a light chain immunoglobulin comprising an amino acid sequence having at least 90% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO:
126 or amino acids 21-131 thereof, and/or
a heavy chain immunoglobulin comprising an amino acid sequence having at least 90% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO:
110 or amino acids 1-119 thereof;
(4)
a light chain immunoglobulin comprising an amino acid sequence having at least 90% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO:
126 or amino acids 21-131 thereof, and/or
a heavy chain immunoglobulin comprising an amino acid sequence having at least 90% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO:
112 or amino acids 1-119 thereof;
(5)
a light chain immunoglobulin comprising an amino acid sequence having at least 90% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO:
126 or amino acids 21-131 thereof, and/or
a heavy chain immunoglobulin comprising an amino acid sequence having at least 90% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO:
114 or amino acids 1-119 thereof;
(6)
a light chain immunoglobulin comprising an amino acid sequence having at least 90% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO:
126 or amino acids 21-131 thereof, and/or
a heavy chain immunoglobulin comprising an amino acid sequence having at least 90% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO:
116 or amino acids 1-119 thereof;
(7)
a light chain immunoglobulin comprising an amino acid sequence having at least 90% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO:
126 or amino acids 21-131 thereof, and/or
a heavy chain immunoglobulin comprising an amino acid sequence having at least 90% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO:
118 or amino acids 1-119 thereof;
(8)
a light chain immunoglobulin comprising an amino acid sequence having at least 90% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO:
126 or amino acids 21-131 thereof, and/or
a heavy chain immunoglobulin comprising an amino acid sequence having at least 90% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO:
120 or amino acids 1-119 thereof;
and
(9)
a light chain immunoglobulin comprising an amino acid sequence having at least 90% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO:
126 or amino acids 21-131 thereof, and/or
a heavy chain immunoglobulin comprising an amino acid sequence having at least 90% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO:
122 or amino acids 1-119 thereof.

43 more elements

Dependencies are inferred from the claim text.

Facts

Application: 15/305,011Filed 17 Aug 2015
Priority: 19 Aug 2014
Published: 12 Oct 2017
Term ends: Not estimatedThe source records don’t support an estimate.

Classification27 codes

A61K 39/39566
Against materials from animals: against immunoglobulins, e.g. anti-idiotypic antibodies
A61K 39/395
Medicinal preparations containing antigens or antibodies: antibodies ; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61K 45/06
Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00: mixtures of active ingredients without…
A61P 31/00
Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics